the fi rst record being cited with the keywords of "saff ron + clinical trial" in Scopus ® belongs to the publications of 1998. The number of such papers has been increased through 2004-2012, 
Introduction

▼
Crocus sativus L (commonly known as saff ron) is a perennial stemless herb from the Iridaceae family that is largely cultivated in Iran and some other countries including Spain, India and Greece [ 1 ] . C. sativus grows up to 20-30 cm height and has 5-11 true leaves that are shielded and covered by 5-11 non-photosynthetic and white leaves (cataphylls). In October, the plant blooms striped purple with a honey-like smell [ 2 ] . Important constituents of saff ron that are pharmacologically active are bitter principles (e. g. picrocrocin), volatile agents (e. g. safranal), and dye materials (e. g. crocetin and its glycoside crocin) [ 1 ] . Although research into eff ects of saff ron is not a new subject and ancient Persian literatures recommend using saff ron as a medicine for treating several diseases, the number of cited documents in medical databases such as Scopus ® have increased over the last 20 years, most of them (78.51 %) being original research. Furthermore, saff ron or its ingredients [ 12 , 16 , 17 ] . It has been also shown that saff ron can promote the diff usivity of oxygen in diff erent tissues [ 17 ] . A number of investigations into safety and toxicity of saffron and its components have been conducted [ 18 -21 ] and some clinical trials about diff erent pharmacological eff ects of saff ron can be found in literatures. In this review, we have discussed strengths and weaknesses of the aforementioned studies.
Pharmacokinetics
▼
Pharmacokinetic evaluation of crocin and crocetin has been carried out in animal and human studies. Pharmacokinetic study of crocin, an active compound of saff ron, in mice showed that it could not be absorbed through the gastrointestinal tract after either a single dose or repeated doses [ 22 ] . Crocin was largely excreted from the intestinal tract following oral administration [ 23 ] . It is hydrolyzed to crocetin before absorption through gastro-intestinal tract [ 22 , 24 ] .
Crocetin is quickly absorbed after oral administration to mice. It can be detected in plasma in free form as well as in the form of a glucuronic acid conjugate [ 22 ] . In rats, a single oral dose of 50 mg/kg crocetin has been shown to have t½ = 30 ± 6 min, t max = 65 ± 16 min, C max = 5.0 ± 1.0 μg/ml, AUC = 845 ± 109 μg × min/ ml, and Vd = 5.0 ± 0.8 l/kg [ 23 ] . The short plasma half-life of crocetin results in rapid elimination without being accumulated in the body [ 23 , 25 ] . Crocetin concentrations in rats' plasma did not tend to accumulate with the repeated doses of oral crocin [ 23 , 24 ] . The concentration-time curve of crocetin has been fi tted with a 2-compartment open model after intravenous administration to rabbit [ 26 ] . Umigai and colleagues investigated pharmacokinetic profi le of crocetin in healthy adult volunteers (5 men and 5 women) in an open-label, single dose escalation study [ 27 ] . Every individual consumed a single dose of crocetin at 3 doses (7.5, 15 and 22.5 mg) with one week intervals. Crocetin was rapidly absorbed in animal studies as well, and could be detected within an hour of administration, reaching to the maximum concentration in 4.0-4.8 h (T max ) [ 27 ] . Additional important pharmacokinetic parameters of crocetin were as follows: C max = 100.9-279.7 ng/ml, AUC 0-24 h = 556.5-1720.8 ng.h/ml, T 1/2 (h) = 6.1 ± 7.2 to 7.5 ± 2.8, CL/F (l/h) = 12.8 ± 2.9 to 13.8 ± 5.4 and Vd/F (l) = 82.8 ± 59.0 to 152.6 ± 80.1 [ 27 ] . These parameters had no signifi cant disparity in diff erent doses, except for C max and AUC 0-24 h , which showed a dose dependent correlation [ 27 ] .
Safety and Toxicity
▼
Saff ron is being used as a food additive for several centuries and this supports its safety for most people. Administrated as medicine, saff ron toxicity and safety required an evaluation. Intraperitoneal LD 50 values of saff ron stigma and petal are reported to be 1.6 and 6 g/kg in mice, respectively [ 28 ] . Nevertheless, it is not toxic when administrated orally with LD 50 value being above 5 000 mg/kg. [ 19 ] . Although ingestion of less than 1.5 g of saff ron is nontoxic for human [ 1 ] , it is considered toxic when ingested with doses more than 5 g and could be lethal if taken about 20 g/day [ 1 , 29 ] . Given that the common eff ective doses being applied in clinical trials are considerably lower than this level (30-50 mg/day), saff ron has a wide therapeutic index.
Mild toxicity with saff ron induce dizziness, nausea, vomiting and diarrhea while a more severe toxicity can cause numbness, tingling in the hands and feet, and yellowish skin and eyes due to precipitation of yellow pigments on the skin and conjunctiva. Spontaneous bleeding may be a symptom as well [ 28 , 30 , 31 ] . A randomized, double-blind, placebo-controlled clinical trial (RDBPCCT) study by Mansoori et al. [ 18 ] evaluated the safety of saff ron administration on sexual dysfunction in 20 adult patients suff ering from major depressive disorder (MDD). The individuals were divided into 2 groups receiving either 15 mg capsules of saff ron or placebo twice daily. Laboratory tests including liver and renal function tests, blood cell count and coagulation tests, were assessed once before the trial and then in 4 weeks. No major laboratory changes were observed in patients receiving saff ron, providing evidences for the safety of this herbal medicine [ 18 ] . Mohamadpour and colleagues, designed a RDBPCCT for safety of crocin tablets (20 mg) in 22 men and women during 1 month [ 32 ] . Also, Modaghegh et al. have evaluated the safety of taking 200-400 mg tablets of ethanolic extraction of saff ron, nearly 4-10 times higher than the recommended therapeutic doses, for 1 week in a RDBPCCT on 30 healthy adults with normal appearance [ 28 ] . Saff ron did not show any considerable adverse eff ects on blood pressure except for decreasing the standing systolic blood pressure and mean blood pressure. They reported no changes in the EKG of the participants [ 28 ] . Neither saff ron nor crocin have had any dose-dependent eff ect on reducing RBC parameters [ 28 , 32 ] . Saff ron has been shown to reduce platelet counts at dose of 200 mg/day [ 28 ] . However, in 2 diff erent studies, Mansoori et al. and Mohamadpour et al., showed a non-signifi cant reduction in such parameters [ 18 , 32 ] . In animal models, saff ron was able to increase coagulation time in mice, and inhibit platelets aggregation in rabbit. These eff ects of saff ron seem to be not related to crocin and safranal, but to adenosine [ 28 , 33 ] . Crocin tablets could have signifi cantly reduced partial tromboplastin time but had no signifi cant eff ect on prothrombin time [ 32 ] . However, crocin in subchronic administration in animal models is shown to reduce levels of serum total cholesterol, triglyceride and low-density lipoprotein cholesterol; inhibit the formation of aortic plaque and have anti-atherosclerosis eff ect due to antioxidant properties [ 34 , 35 ] . There was no change in the lipid profi le of individuals ingesting saff ron in Modaghegh et al. study [ 28 ] . Mohamadpour also reported insignifi cant changes in lipid profi le of patients who were treated with crocin in comparison with control [ 32 ] . Nevertheless, diet programs of groups in the 2 mentioned studies did not match. Administration of 200 and 400 mg/day of saff ron for 1 week elevated creatinine (Cr) and blood urea nitrogen (BUN) levels [ 28 ] . However, Mansoori et al. did not report any changes in the renal parameters 4 weeks following the ingestion of 30 mg/day of ethanolic extract of saff ron, and so did Mohamadpour et al. [ 18 , 32 ] . This diff erence seems to be related to the dose and the sampling time. Renal toxicity of saff ron has also been mentioned in traditional medicine [ 18 ] . Mohajeri rus), liver function tests and hormone levels (thyroxine, thyroidstimulating hormone, cortisol and testestron) between placebo and crocin-treated (2 mg/d) groups [ 32 ] . Serum concentrations of crocin and crocetin had not been reported by any of the mentioned studies.
Given that the majority of crocin is not absorbed via gastrointestinal tract, it might have given a better estimation of pharmacokinetic-pharmacodynamic relationship for crocin, if researchers had evaluated serum levels of crocin or crocetin.
In some of the clinical trials about the effi cacy of saff ron in the Alzheimer disease and depression, 15-30 mg/day of saff ron capsule were prescribed and several minor adverse eff ects such as nausea, vomiting, dizziness, dry mouth and etc. have been reported. The commonest adverse eff ect of saff ron was dry mouth (18 and 13 %) [ 36 -39 ] . In a report by Modaghegh and colleagues in which they had treated their precipitance with higher doses, no minor adverse eff ects were mentioned. Such diff erences in these studies are probably related to the duration of treatment. Gout reported a few minor adverse eff ects such as nausea, diarrhea, and refl ux in about 16 % of volunteers; the overweight women receiving 174.5 mg/day of saff ron for 8 weeks. These side eff ects were no more than the placebo group [ 40 ] . On the other hand, it may be associated with recall bias in neurologic clinical trials in which researchers mentioned similar instances of adverse eff ects. The authors reported no signifi cant diff erence between saff ron and placebo regarding the side eff ects. Correlation between advancing age and rate of adverse drug reaction has been shown in some studies [ 41 ] and it may be another reason for such variation. For instance, the average age in Modaghegh's study (27.4-30 years) was lower than that in neurologic clinical trials (35-73years). Modaghegh et al. reported abnormal uterine bleeding in one female in each group of 200 and 400 mg of saff ron. As documented in traditional medicine, saff ron had been used for abortion [ 39 ] , and later in was shown to be able to induce uterine stimulants and have estrogenic eff ects in guinea pigs and mice, respectively [ 42 ] . This type of side eff ects were not described in Gout's study on 60 women with doses near to that of Modaghegh's study but with extended duration [ 40 ] . We could not fi nd any study on the interactions between diff erent drugs and saff ron. However, in patients under anticoagulant therapy or those having certain types of renal insuffi ciency, a cautious approach for prescribing saff ron is suggested.
Cardiovascular
▼
The eff ects of crocin, an active constituent of C. sativus , have been studied in isoproterenol-induced cardiotoxicity in rats [ 43 ] . Either crocin (5, 10 and 20 mg/kg/day) or vehicle were administered orally for 21 days together with isoproterenol (85 mg/kg, subcutaneously, every 24 h) on the last 2 days in order to induce cardiac dysfunction, which was indicated as low blood pressure. The results illustrated a possible cardioprotective eff ect for crocin in isoproterenol-induced cardiac toxicity via modulating oxidative stress resulted in maintaining the redox status of cells [ 44 ] . It has been shown that the aqueous extract of saff ron stigma has hypotensive eff ect in rats, which is partly due to the actions of its 2 major constitutes, crocin and safranal; taking into account that safranal plays a greater role in decreasing the blood pressure in comparison to crocin [ 45 ] .
In RDBPCCT used saff ron tablets for one week on 30 healthy volunteers divided into 3 groups of placebo, 200 and 400 mg saffron. The results demonstrated that saff ron at dose of 400 mg could signifi cantly decrease standing systolic blood pressure and mean arterial pressures and increase serum sodium, BUN and Cr. The biochemical changes were within the normal ranges and turned out to be clinically insignifi cant [ 28 ] . In addition, it has been shown that aqueous-ethanolic extract of saff ron has a potent inhibitory eff ect on calcium channels of guinea pig isolated heart [ 46 ] . It has long been revealed that crocetin can almost completely prevent the induced atherosclerosis in rabbits, most likely through increasing the oxygenation of tissues [ 47 ] . In another study on rabbits, in which 2 out of 3 groups of animals received either high lipid diet alone or high lipid diet plus crocetin, crocetin was shown to have anti-atherosclerotic eff ect since it suppressed the expression of vascular cell adhesion molecule-1 (VCAM-1), which might be due to deactivation of NF-kappa B [ 48 ] . However, there have been reports that the incidence of cardiovascular diseases is noticeably lower in the geographic parts where saff ron is used in daily diet of inhabitants [ 49 ] , taking into account that antioxidants and fl avonoids, especially lycopene, that exist in saff ron are proven to decrease the risk of cardiovascular diseases [ 50 ] .
A clinical trial was held by Verma et al., showed the prospective eff ects of saff ron on cardiovascular disorders. In this study, 50 mg of saff ron was dissolved in 100 ml of milk and administered twice a day to 20 individuals, 10 of them suff ering from heart disease. A constant decrease in lipoprotein oxidation susceptibility was investigated after 3 and 6 weeks; hence, the signifi cant drop in LOS levels indicated a potential antioxidant eff ect for saff ron [ 51 ] . Taking into account the anti-atherosclerotic, antioxidant, antidiabetes, hypotensive, anti-ischemic, anti-platelet aggregation and hypolipidemic eff ects of saff ron, this herb can be considered as a promising treatment in decline of cardiovascular risk factors.
Neuropsychology
▼
Alzheimer disease
Alzheimer disease (AD) is the most frequent form of dementia [ 52 ] . It is estimated that 42 million people worldwide will suff er from AD by 2040 [ 53 ] and it will reach epidemic proportions. Diagnosis of AD is based on criteria and symptoms. The most common symptom pattern begins with a gradually worsening diffi culty in remembering new information [ 53 ] . Few drugs have been developed to alleviate these cognitive symptoms, thus more practical and safe medications are required for the cognitive, behavioral and psychological symptoms of dementia [ 54 ] .
Crocin and safranal are shown to inhibit the formation of soluble oligomers and following fi brillar assemblies in cell culture. It is assumed that they bind to hydrophobic patches provided in the intermediate structures and thereby inhibit protein aggregation. The simultaneous hydrophobic and hydrophilic properties of crocin result in a more eff ective action [ 54 ] . Due to antioxidant properties of C. sativus stigma constituents [ 13 , 56 ] , they are eff ective in Abeta fi brillogenesis and deposition in a concentration and time-dependent manner [ 57 ] . Abeta fi bril formation and deposition is thought to be promoted by oxidation [ 57 ] . Diffuse and neurotic extracellular amyloid plaques and intracelluThis document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
lar neurofi brillary tangles in the hippocampus, cerebral cortex and other areas of the brain, that are essential for cognitive function, is considered to be associated with AD and other neurodegenerative disorders such as Parkinson disease [ 53 , 55 , 58 ] . Chronic microglial activation produces various pro-infl ammatory and neurotoxic factors that induce neuronal injury [ 7 ] ; therefore, negative regulation of microglial activation is an alternative to treat neurodegenerative disorders. In cultured microglial cells of rat brain, crocin and crocetin could inhibit LPS-induced nitric oxide (NO) release and result in reducing tumor necrosis factor-alpha, interleukin-1beta, and intracellular reactive oxygen species, as well as showing neuroprotection eff ect and inhibiting the hippocampal cells death [ 7 ] . Shams and colleagues reported that aqueous extract of saff ron can improve learning and memory. Their results also indicated that aqueous extract of saff ron increases brain dopamine and glutamate concentrations, whereas it could change neither brain serotonin nor norepinephrine [ 58 ] . The eff ectiveness of saff ron extract and crocin on memory enhancing in chronic cerebral hypoperfusion in rat has been reported [ 16 ] . It was reported that administration of C. sativus extracts could antagonize ethanol, acetaldehyde and scopolamine-induced memory impairment in rat and mouse [ 10 , 13 , 59 ] There are 2 clinical trials on patients with mild-to-moderate AD [ 36 , 37 ] , the fi rst one being a 16-week, RDBPCCT [ 36 ] and the second being a 22-week, multicenter, RDBPCCT [ 37 ] . On both studies, diagnosis of AD was based on the criteria of Diagnostic and Statistical Manual of Mental Disorders. Effi cacy of treatment was evaluated by changing in AD Assessment Scale and cognitive subscale and Clinical Dementia Rating Scale. Akhondzadeh et al. treated patients with dose of 30 mg/day (15 mg twice a day) of saff ron or placebo for 16 weeks in fi rst, and also with either 30 mg/day saff ron capsules (15 mg twice a day) or donepezil 10 mg/day (5 mg twice a day) for 22 weeks in the second study [ 36 , 37 ] . Authors reported that saff ron produced a signifi cantly superior outcome on cognitive function than the placebo. They also showed that the eff ectiveness of saff ron on improving the cognition score of AD patients was equal to that of donepezil, both decreasing the score in Alzheimer's Disease Assessment Scale by about 3.7, and the score of Clinical Dementia Rating Scale by 0.7-0.8. Although saff ron was shown to possess adverse eff ects, they were no more than the placebo or donepezil. Both studies were designed very well as multicenter doubleblind clinical trials, although they did not completely defi ne the etiology in their patients [ 36 , 37 ] . Prescribing saff ron for AD patients requires more extended studies with bigger sample size and diff erent types of etiologies.
Depression
Depression is the fourth cause of disability worldwide [ 60 ] . In Persian traditional medicine, saff ron is used for depression [ 62 ] . Hosseinzadeh et al. reported the antidepressant eff ect of C. sativus stigma extracts as well as safranal and crocin in mice being assessed by forced swimming test. Safranal (0.15-0.5 ml/kg) and crocin (50-600 mg/kg) could reduce the immobility time, and both extracts increased swimming time similar to fl uoxetine and increased climbing time like to imipramine [ 61 ] . It seems that crocin may inhibit uptake of dopamine and norepinephrine, and safranal acts via serotonin [ 6 , 61 ] . There are some other papers about eff ectiveness of saff ron against depression on different animal models [ 5 , 63 , 64 ] . Saff ron has also been reported to have anxiolytic eff ects in animal models [ 65 ] .
C. sativus extract has been used in some antidepressant clinical trials ( • ▶ Table 1 ). The antidepressant eff ects of saff ron were compared with placebo in 2 studies [ 38 , 39 ] , with fl uoxetine in 2 studies [ 62 , 66 ] , and with imipramine in one study [ 60 ] . Another study compared outcome of patients who received combination of fl uoxetine with saff ron or placebo [ 18 ] .
Researchers have attempted to perform clinical trials on most typical antidepressants with the inclusion criteria, such as age ranges (18-65 years old) and frequency of genders, and exclusion criteria, e. g. co-morbidity of psychiatric illness, specifi c types of personality disorders etc. [ 67 ] . Participants were outpatients who met the DSM-IV criteria for major depression (mild to moderate depression). Sample size were equal (n = 30-40) in all studies, although some of the reviewers stated that their sample sizes were not enough [ 68 ] . All of these studies were performed on similar population. Based on clinical trial guidelines, a minimum of 4-6 weeks appear to be an appropriate duration [ 67 ] which has been observed by all of them; although, this could not refl ect the preventive eff ect of saff ron on exacerbation of depression and needs to be evaluated in extended studies. In 2 studies [ 38 , 39 ] which compared saff ron with placebo, authors reported no signifi cant diff erences between the 2 groups in terms of observed side eff ects. Nevertheless, it seems that the total number of reported adverse eff ect by patients in saff ron group were more than that of control (29 vs. 13 and 17 vs. 10).
The most frequent adverse eff ect of saff ron which had been reported in all trial was anxiety ( • ▶ Table 2 ) followed by an increase or a decrease in the appetites, nausea and headache. None of these studies had any report about past medical history of their participants. This is not entirely obvious whether they were treated with other medications before being included in the study. Furthermore, the authors did not completely defi ned whether patients were treated with other psychological treatments, such as psychotherapy or family therapy. Through our review of the literatures, we found another clinical trial on the eff ect of saff ron on premenstrual syndrome [ 69 ] . The researchers had used 17-item HAM-D scoring for evaluating the outcome. They showed that administration of 30 mg/day (15 mg twice a day) saff ron capsules for 2 menstrual cycles could reduce the depression score as well as the menstruation symptoms ( • ▶ Table 1 ) in comparison to placebo. The most reported adverse eff ect of saff ron on this study was a change in appetite ( • ▶ Table   2 ). We also found 2 other abstracts of clinical trial on antidepressant eff ect of saff ron that were presented in congresses as poster presentation. They had evaluated the antidepressant eff ect of saff ron by BECK depression score [ 70 , 71 ] . One abstract had studied eff ect of drinking a saff ron-containing tea for 4 weeks in medical students. It was revealed that saff ron could reduce depression score [ 70 ] . The aim of the other study was to evaluate the eff ect of 100 mg/day saff ron vs. placebo in 70 patients for 12 weeks [ 71 ] , also reporting the eff ectiveness of saff ron. However, these 2 studies had a bigger sample sizes (n = 50 and 70) and a longer treatment duration (4 and 12 weeks) than the previous This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. studies. Since the abstracts were only published, we could not assess the studies thoroughly. It seems that now is the time for evaluating antidepressant eff ect of saff ron by multicenter, crossover, and large scale as third phase of clinical trials.
Physical fatigue
Production of reactive oxygen species and free radicals, which are responsible for exercise-induced protein oxidation and contributes to physical fatigue, is promoted during muscular exercise [ 72 , 73 ] . Administration of crocetin as an antioxidant [ 56 , 74 ] may attenuate physical fatigue. Mizuma and colleagues evaluated effi cacy of 15 mg of crocetin in a double-blind, placebocontrolled, 3-way crossover study on physical fatigue in 14 Japanese healthy volunteers (7 men and 7 women) for 8 days [ 75 ] . They administrated crocetin (15 mg/day), ascorbic acid (3 000 mg), or placebo capsules for 1 week before the experimental procedure. They found that men, who received crocetin alone, had signifi cantly higher change in maximum velocity from 30-to 210-min. They could not fi nd such diff erence in women [ 75 ] . The authors related their fi nding to antioxidant and alveolar oxygen transport augmentation properties of crocetin. However, they had not measured and reported any oxidant or antioxidant biomarkers or criteria of oxygenation.
Endocrinology and Gynecology
▼ Erection dysfunction (ED) and infertility
Recently, diff erent herbal remedies have been assessed as eff ective treatments for male infertility and other male sexual dysfunctions. Saff ron has been known for centuries to have aphrodisiac properties. Moreover, the aphrodisiac activities of saff ron aqueous extract and its constituent crocin, in male rats have been previously declared [ 76 ] . In a pilot clinical study on 20 men with erectile dysfunction, patients were observed for 10 days taking 200 mg tablets of saffron every morning. The results showed a statistically signifi cant improvement in both tip and base rigidity and tumescence. Moreover, saff ron was considered positively eff ective on sexual function of patients with erectile dysfunction even after a shorttime treatment [ 77 ] . However, this was a pilot study and the sample number was rather few. Additionally, there were no control group and no placebo was utilized. In a similar study to assess the effi cacy and safety of saff ron in erectile dysfunction, after 4 weeks of baseline evaluation, 346 men with erectile dysfunction received Sildenafi l or saff ron (30 mg BID) for 12 weeks. No signifi cant improvements were observed in the international index of erectile function domains, Sexual Encounter Profi le questions and Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire scores with saff ron administration. The authors reported that their fi ndings did not support benefi cial eff ects of saff ron administration in men with erectile dysfunction [ 78 ] . This might be attributed to the low dose of saff ron (30 mg BID) prescribed in comparison to the previous study.
On the other hand, Safarinejad et. al studied the eff ect of saff ron vs. placebo on idiopathic male factor infertility on 260 infertile men with idiopathic oligo-asthenoteratozoospermia (OAT).
Patients received either 60 mg/day saff ron or placebo for 26 weeks. Afterwards, the 2 groups were compared with each other regarding changes in semen parameters and total seminal plasma antioxidant capacity. The results of the study showed saff ron did not improve semen parameters in infertile men with idiopathic OAT [ 79 ] . In a case-report a 25-year-old woman with a 2-year primary infertility who was diagnosed with unilateral tubal blockage, received Unani herbal Majoon, one of its ingredients being C. sativus , for 2 successive cycles. The outcome was the patient's pregnancy 2 months after therapy. C. sativus L. was reported to recover infertility due to crocetin and fl avonoids contents. [ 80 ] . Nevertheless, it cannot be directly concluded whether or not the positive result was due to saff ron.
Premenstrual syndrome (PMS)
The eff ect of saff ron has been studied on some gynecologic disorders, mostly on premenstrual syndrome (PMS). PMS is a group of cyclical and recurrent emotional, physical, psychological, and mood discomfort that typically occurs after ovulation and before the onset of menstrual period [ 81 ] . A RDBPCCT study investigated the eff ect of stigma of saff ron on relieving the symptoms of this syndrome on 20-45 aged women with; regular menstrual cycles and the experience of the symptoms of PMS for at least 6 months.They received either 30 mg per day saff ron or placebo. PMS symptoms were evaluated using a Premenstrual Daily Symptoms (PDS) questionnaire and Hamilton Depression Rating Scale (HAM-D). There was a signifi cant diff erence in the effi cacy of saff ron in the Total PDS and HAM-D.
The results indicated the positive eff ect of C. sativus L. in alleviation of PMS symptoms [ 69 ] .
Primary dysmenorrhea
Primary dysmenorrhea, with a prevalence rate of approximately 90 %, is described as cramping pains in the lower abdomen before or throughout the menstruation period without the presence of other diseases [ 82 ] . The eff ect of saff ron has been assessed in the treatment of primary dysmenorrhea using a pilot RDBPCCT on 180 female students aged 18-27 years old suff ering from primary dysmenorrhea. Individuals were randomly divided into 3 groups taking either herbal drugs (saff ron, celery seed, and anise extracts 3 times a day for 3 days) or mefenamic acid or placebo, starting from the onset of bleeding or pain. Severity and duration of pain were evaluated for 3 months. Both herbal and chemical drugs effi ciently comforted the menstrual pain in comparison with the placebo [ 83 ] . However, since the herbal drug contained 3 herbs, this eff ect cannot be attributed to a specifi c herb.
Another study attempted to elucidate the eff ects of saff ron odor on some gynecologic symptoms including PMS, dysmenorrhea and irregular menstruation. 35 women with normal olfactory ability and normal menstrual cycles were exposed to saff ron odor for 20 min. Saliva samples were subsequently analyzed for cortisol, testosterone and 17-beta estradiol concentrations utilizing enzyme immunoassay method. The State-Trait Anxiety Inventory (STAI) was used for psychological testing. The outcome was a considerable decline in cortisol levels and an increase in estradiol levels after exposure to saff ron odor in both follicular and luteal phases. Moreover, the STAI score decreased in the follicular and luteal phases in the saff ron group. Therefore, the fi ndings of this RDBPCCT suggested positive physiological and psychological eff ects of saff ron odor in management of PMS, dysmenorrhea and irregular menstruation [ 84 ] . However, in this study the fragrance of saff ron was diluted in ethanol to be This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
smelled by the test individuals, a fact that implies that such solvent may be considered an eff ective treatment.
Snacking and appetites
Snacking and compulsive eating are disturbed dietary behaviors which are consequence of mood disorders. Stress-induced eating accompanied with a preference for high-sugar and high-fat food consumption, is powerful reinforcing of snacking [ 85 ] . Several studies have shown mood elevation and anti-anxiety properties of saff ron [ 39 , 61 , 65 , 66 ] . Gout et al. evaluated the eff ect of saff ron on reducing the snacking frequency and demand, in 60 healthy, mildly overweight women, during a RDBPCCT [ 40 ] . They administrated 176.5 mg extract of saff ron or placebo per day over an 8-week period and recorded body weight changes and snacking frequency. They found that saff ron caused a signifi cantly greater body weight reduction than the placebo after 8 weeks, and a signifi cant decrease in snacking frequency after 4 weeks. However, other anthropometric dimensions and vital signs did not not change between the saff ron and placebo groups [ 40 ] . They reported no major adverse eff ects as well. Therefore, they have off ered saff ron as an adjuvant supplement for people involved in weight loss programs whose weight gain is particularly due to stress or depression [ 40 ] .
Immunology and Allergy ▼ Feo et al. have studied the sensitization to saff ron and its clinical signifi cance as an occupational allergen [ 86 ] . In their study, 2 groups of subjects were included: one group was exposed to saffron in an important saff ron area of Spain as workers (picking, manual extraction of stigmas, and roasting the stigmas of saffron), and the other group comprised of 237 unexposed patients with a positive history of allergy. Individuals having positive Skin Prick test afterward went through Radioallergosorbent test (RAST) to evaluate the cutaneous and specifi c antibody responses. Saff ron allergens from pollen and stamens were then characterized by SDS-PAGE immunoblotting. No allergens were verifi ed in pistils [ 86 ] . In another study directed in Iran, more than 200 saff ron workers referring to an allergy clinic were evaluated regarding the clinical symptoms and Prick test. Results illustrated that saff ron, and in particular its pollen, was an inhalation allergen and female workers were more sensitive to this plant than the male ones [ 87 ] . The eff ects of 100 mg saff ron tablets taken daily for 6 weeks, were evaluated on 45 healthy middle-aged men through a RDB-PCCT [ 88 ] . Diff erent hematological and immunological parameters were assessed 3 weeks after treatment. Saff ron increased IgG levels while decreasing IgM levels in comparison with the baseline and the placebo. Moreover, it could decrease the percentage of basophils and also the platelets count, but it increased the percentage of monocytes. The results of this study suggested that a sub-chronic daily dose of 100 mg saff ron had short-term immunomodulatory eff ects with no side eff ects [ 88 ] .
Skin
▼
As one of the Persian traditional medications, saff ron, has been used in order to add shine, lighten the skin and reduce dark pigments, dark circles under the eyes, acne and pimple [ 89 ] . It is suspected that crocin inhibits active compound of DNA damage, or acts as an activator for DNA excision repair enzymes [ 90 ] . Furthermore, saff ron has antisolar eff ect and can absorb UV rays of sun [ 91 ] . Vyas et al. used 3 % dry extract of saff ron being inoculated in o/w cream, lotion and face powder formulations and tested it by patch test on individuals in age groups of 18-28. They reported that saff ron could clearly enlighten the skin. They suggested these eff ects are due to crocin and crocetin presented in saff ron [ 92 ] . The shining and depigmentation eff ects of saff ron may be attributable to antioxidant eff ect of crocin and crocetin [ 17 , 93 ] . However, Vyas had no appropriate methodological clinical trial criteria such as number of groups, control group and the human method. We could not fi nd any other article about the eff ect of saff ron on skin. Saff ron has been used as an ingredient in anti-itching creams possessing emollient and antipruritic eff ects in a unicentric, open label randomized controlled study [ 94 ] . For the case group, a topical polyherbal formulation cream containing extracts of turmeric 16 % ( Curcuma longa ), saff ron 0.025 % ( C. sativus ), sandalwood 8 % ( Santalum album ), vetiver 0.5 % ( Veteveria zizanioides ), lata kasturi 0.1 % ( Abelmoschus moschatus ), mehendi 3 % ( Lawsonia inermis ), tulasi 3 % ( Ocimum sanctum ), yastimadhu 0.5 % ( Glycyrrhiza glabra ), turmeric oil 0.1 %, surasar 0.5 %, and swarna bhasma 0.00032 % in a nongreasy cream base was used. They applied standard antipuritic cream containing urea, lactic acid, propylene glycol and light liquid paraffi n. They reported that this application could reduce both pruritus and composite scores in case group as well as in the control standard group. Adverse events like mild local skin irritation and burning sensation at the site of application were reported in only 3 out of 25 cases, being as frequent as in the control group [ 94 ] . However, this is the only clinical trial on antipuritic eff ect of saff ron and the results are not utterly related to saff ron.
Conclusion
▼
Saff ron and its constituents are shown to possess multiple useful eff ects on several diseases such as Alzheimer and depression as well as in gynecology disorders. Due to high safety level of this phytomedicine, it can be applied in clinical trials for majority of its eff ects. Some applications of saff ron such as antidepressant and anti-Alzheimer properties are suffi cient for the subsequent phase of clinical trials or drug developments. However, most of others eff ects and applications of saff ron require further clinical and animal studies.
